Formulation and Specifications: Injection: 100 mg (4 ml)/vialIndications: First-line treatment for patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 (composite positive score…
Formulation and specifications: Injection: 100mg (20ml)/vialIndications: This product is used for the treatment of squamous cell carcinoma of the head and neck: in combination with platinum and fluorouracil chemotherapy for…
Formulation and Specifications: Injection: 40mg (4ml)/vial, 100mg (10ml)/vialIndications: This product is indicated for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma who develop disease…
Formulation and specifications: Tablets: 8mg, 10mg, 12mgIndications: For the treatment of patients with unresectable, locally advanced or metastatic medullary thyroid cancer with clinical symptoms or definite disease progression.Key points for…
Formulation and Specifications: Capsules: 4mg, 10mgIndications: Patients with progressive, locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer.Key points for rational dosing:1. The recommended daily dose is 24 mg once daily…
Formulation and Specifications: Tablets: 200 mgIndications: Treatment of locally recurrent or metastatic progressive radioiodine-refractory differentiated thyroid cancer.Key points for rational dosing:1. Administered on an empty stomach, no genetic testing is…
Formulation and specifications: Powder injection: 200mg/vialIndications:1. This product is used for the treatment of patients with advanced nasopharyngeal carcinoma whose disease has progressed or is intolerable after receiving previous second-line…
Formulation and specifications: Injection: 80mg (2ml)/bottle, 240mg (6ml)/bottleIndications: For the treatment of patients with recurrent/metastatic nasopharyngeal carcinoma who have failed previous second-line and higher systemic therapy.Key points for rational drug…
Formulation and specification: Injection: 50mg (10ml)/bottleIndications: Combined with radiotherapy for the treatment of stage III-IV nasopharyngeal carcinoma with positive expression of EGFR gene.Key points for rational drug use:1. The first…